Why Molecular Testing is Increasingly Important in CNS Cancers
Primary and metastatic central nervous system (CNS) tumors can have extraordinary biological and anatomical complexity, and these tumors can be hard to identify using traditional imaging or histopathology analysis. Molecular analysis has emerged as a major way to identify these tumors and help medical teams plan how best to help those diagnosed with these cancers.
Biomarker testing is a growing field that is making it possible for the molecular structure of CNS cancers to be analyzed for not only diagnostic purposes but also other functions as well. Recent advances like the detection of tumor RNA particles in blood samples now mean that a brain cancer can be identified and tracked without subjecting patients to surgical procedures to get a tumor sample.
Molecular profiling is taking on increasing importance because it allows treatment teams to correctly classify or grade a given cancer. For example, rare brain cancers like DMG (diffuse midline glioma) are not only complex biologically but also affect a very small number of individuals globally. Biomarker testing helps clinicians to accurately identify such cancers and grade them correctly so that the next steps can be based on accurate information.
Detailed molecular profiling also makes it possible to make the right treatment decisions. For example, molecular tests can be used to monitor how a patient is responding to their treatment and any necessary adjustments to the treatment regimen can be made in a timely manner based on the data collected from the biomarker tests done.
Another key benefit of conducting comprehensive molecular tests is that it makes it possible for patients, such as those suffering from rare brain cancers, to be eligible for ongoing or planned clinical trials. Cancer therapy is advancing at a fast pace, and clinical trial participation offers patients an opportunity to access new treatments at a time when some patients may have limited options that can address the specific malignancy they have been diagnosed with.
Biomarker testing also makes it possible for patients to access therapies that could save their lives or extend their survival. For instance, new treatments that target particular genetic mutations behind some cancers are emerging.
When molecular tests are done and confirm that a patient’s CNS cancer is linked to a particular mutation, such as the H3 K27M oncogenic mutation in DMG (diffuse midline glioma), such a patient can be put on available therapies targeting that mutation. Consequently, the survival of the patient can be extended and the progress of the cancer could be slowed down.
As companies like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) advance their drug development efforts with a focus on central nervous system cancers, greater awareness of biomarker testing by the medical community and patients may be a huge step in matching these emerging treatments with the patients who need them the most.
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Primary and metastatic central nervous system (CNS) tumors can have extraordinary biological and anatomical complexity, and these tumors can be hard to identify using traditional imaging or histopathology analysis. Molecular analysis has emerged as a major way to identify these tumors and help medical teams plan how best to help those diagnosed with these cancers.
Biomarker testing is a growing field that is making it possible for the molecular structure of CNS cancers to be analyzed for not only diagnostic purposes but also other functions as well. Recent advances like the detection of tumor RNA particles in blood samples now mean that a brain cancer can be identified and tracked without subjecting patients to surgical procedures to get a tumor sample.
Molecular profiling is taking on increasing importance because it allows treatment teams to correctly classify or grade a given cancer. For example, rare brain cancers like DMG (diffuse midline glioma) are not only complex biologically but also affect a very small number of individuals globally. Biomarker testing helps clinicians to accurately identify such cancers and grade them correctly so that the next steps can be based on accurate information.
Detailed molecular profiling also makes it possible to make the right treatment decisions. For example, molecular tests can be used to monitor how a patient is responding to their treatment and any necessary adjustments to the treatment regimen can be made in a timely manner based on the data collected from the biomarker tests done.
Another key benefit of conducting comprehensive molecular tests is that it makes it possible for patients, such as those suffering from rare brain cancers, to be eligible for ongoing or planned clinical trials. Cancer therapy is advancing at a fast pace, and clinical trial participation offers patients an opportunity to access new treatments at a time when some patients may have limited options that can address the specific malignancy they have been diagnosed with.
Biomarker testing also makes it possible for patients to access therapies that could save their lives or extend their survival. For instance, new treatments that target particular genetic mutations behind some cancers are emerging.
When molecular tests are done and confirm that a patient’s CNS cancer is linked to a particular mutation, such as the H3 K27M oncogenic mutation in DMG (diffuse midline glioma), such a patient can be put on available therapies targeting that mutation. Consequently, the survival of the patient can be extended and the progress of the cancer could be slowed down.
As companies like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) advance their drug development efforts with a focus on central nervous system cancers, greater awareness of biomarker testing by the medical community and patients may be a huge step in matching these emerging treatments with the patients who need them the most.
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
